分类归档 sangna

Special feature of 1905 film network A bowl of "ecstasy rice" and a "peeing cow pill" saved the hero who was at the bottom of his life — — Stephen Chow also saved his precarious acting reputation.

After a lapse of 28 years, the film will soon land in the mainland cinema on August 31. Let’s go back to 1996 with Professor Suo Yabin of China Communication University, and see what kind of inner monologue Stephen Chow hides in The God of Food, and how it makes Stephen Chow return to the peak, from "Star Boy" to "Star Master".

Stephen Chow: Life from Greasy to Vicissitudes

The God of Food is known as Stephen Chow’s "semi-autobiographical film". The hero Stephen Chow not only has the same English name as Stephen Chow, but also has a similar life experience as Stephen Chow 28 years ago.

At the beginning of the film, Steven Chow subverts Stephen Chow’s previous screen image. He is a greasy and successful middle-aged man, and after the selection meeting of the God of Food, he lambasted the chefs for their incompetence.

After experiencing the ups and downs of life, Stephen Chow is full of silver hair and is full of vicissitudes. This model became a classic image that Stephen Chow appeared in the public eye after, which is also his self-understanding of his middle-aged image.

Before filming "The God of Food", Stephen Chow set up his own business, suffered losses in investing in filming, and refused the request of the film producer for a pay cut, and was labeled as "playing big cards" for a time. Before the release of Gourmet, the media reported gloating and bluntly said, "Stephen Chow eats porridge and depends on Gourmet.

Suoyabin:Stephen Chow may have put a lot of bitterness and frustration in his life into "The God of Food". The changes in his style in the film also reflect Stephen Chow’s self-orientation.

Gourmet vs

From unwilling to open-minded

The God of Food and king of comedy are important turning points in Stephen Chow’s acting career. In Stephen Chow’s creative sequence, these two films are the two works that can best express his personal life experience.

Suoyabin:These two works have a sense of yin and yang. The two awards in "The God of Food" are all manipulated by shady people, which directly expresses Stephen Chow’s dissatisfaction with the awards of the Hong Kong Film Awards. This is even more obvious in the previous films co-directed by Stephen Chow.

But this "bitterness" disappeared in king of comedy three years later. Perhaps because it has spread in the mainland at this time, Stephen Chow has been recognized by the audience again, or even further, perhaps because he has put down his obsession with awards, and he has been open-minded at this time. It doesn’t matter whether I succeed in the secular sense or not if I insist on my love and find my own stage in king of comedy. Stephen Chow’s understanding of life is also much more open-minded: if I want to regain the recognition of the audience, I must recognize this normal heart.

A mixture of joy and sadness: from Star Boy to Star Master

There are some golden sentences in many of Stephen Chow’s works, such as "Everyone is a god of food with his heart" in "God of Food" and "Everything is dark in front of him" in "king of comedy". No, it will be beautiful after dawn. " These golden sentences are full of joy on the surface, but in fact they are taking pains.

Suoyabin:There is a mixed feeling in Stephen Chow’s films. He successfully mixes the humble, the small, the great, the lofty, the sad and the happy. Don’t let the audience immerse themselves in a certain emotion for too long, but let people keep spinning in this complicated emotion. For example, in "king of comedy", Yin Tianchou (Stephen Chow) and Liu Piaopiao (Liu Piaopiao) watch the scenery at night, but there is nothing in front of them, and they have to comfort themselves there. But if we think about it, it is precisely because we have to work during the day to make money that we choose to enjoy the scenery at night.

The core of comedy is tragedy, and to a certain extent, Stephen Chow also achieved this. Starting from The Gourmet, Stephen Chow’s series of director’s works have shifted from label-based features to insight into human nature, which is also an important turning point for Stephen Chow from "Star Boy" to "Star Master".

Although Stephen Chow is no longer prolific, it seems that the voice waiting for his new works is still the more mainstream voice in the audience.

Then, why do we go to the cinema to watch an old movie "The God of Food"?

Suoyabin:This may have a variety of mentality, for example, to "Star Master" a movie ticket, or like me, I especially want to see how expressive the "God of Food" is on the big screen. Take a look at how Stephen Chow, who wants to transform in middle age but is still facing troubles, gropes her way forward in a desperate situation.

　　Lanzhou Intermediate People’s Court of Gansu Province

　　Criminal verdict

　　(2020) Gan 01 was sentenced to No.37.

　　The original public prosecution organ is the People’s Procuratorate of Yuzhong County, Gansu Province.

　　Appellate unit (defendant in the original trial) Gansu Yalan Pharmaceutical Co., Ltd., unified social credit code 91620123745890028F, domicile: No.148, Gongmao Street, heping town, Yuzhong County, and legal representative Dong Wanyou.

　　Litigation representative Li, male, Han nationality, born on September 5, 1969, is the general manager of Gansu Yalan Pharmaceutical Co., Ltd. and lives in Chengguan District of Lanzhou City.

　　Defender Xie Yanren, lawyer of Gansu Qiming Law Firm.

　　Appellant (defendant in the original trial) Peng Mou, male, Han nationality, born on December 28, 1968, with a university education, is from Chengguan District, Lanzhou City, Gansu Province, and is the director of the third marketing department of the sales management center of Gansu Yalan Pharmaceutical Co., Ltd., living in Chengguan District, Lanzhou City. On April 14, 2017, he was released on bail pending trial by Yuzhong County Public Security Bureau on suspicion of producing and selling counterfeit drugs. On January 2, 2018, he was released on bail pending trial by Yuzhong County People’s Procuratorate.

　　Defender An Aiming, lawyer of Gansu Sailai Law Firm.

　　The People’s Court of Yuzhong County of Gansu Province tried the case that the People’s Procuratorate of Yuzhong County of Gansu Province accused the defendant Gansu Yalan Pharmaceutical Co., Ltd. (hereinafter referred to as Yalan Pharmaceutical Co., Ltd.) and the defendant Peng Mou of committing the crime of producing and selling counterfeit drugs, and made a criminal judgment of (2019) Gan 0123 Chu No.51 on November 28, 2019. After the verdict was pronounced, both the defendant Yalan Pharmaceutical Co., Ltd. and the defendant Peng Mou in the original trial refused to accept it and filed an appeal. Our court appealed according to law. The trial is now over.

　　The judgment of Yuzhong County People’s Court in Gansu Province found that:

　　In 2009, the defendant Peng went to work in Yalan Pharmaceutical Company, engaged in the procurement and sales of Chinese herbal medicines. On March 25th, 2015, the defendant Peng was appointed by Yalan Pharmaceutical Company as the Director of Marketing Department 3 of the Sales Management Center, responsible for the raw material procurement, processing and finished product sales of Chinese herbal pieces.

　　In February 2014, the defendant Pengmou purchased 3.2 kg of raw materials of Rhizoma Drynariae from Lanzhou Yellow River Market, and put into production 3 kg of Chinese herbal pieces of Rhizoma Drynariae with batch number of 140201 on February 8, at the price of 28 yuan per kg. This batch of Chinese herbal pieces was sold to Gansu Longyou Pharmaceutical Logistics Co., Ltd. on April 14, 2015. On August 18th, 2015, the Food and Drug Administration of Chengguan District, Lanzhou City sampled the batch of Chinese herbal pieces of Rhizoma Drynariae from Gansu Longyou Pharmaceutical Logistics Co., Ltd., and on October 12th, 2015, it was inspected by Lanzhou Food and Drug Inspection Institute, and the conclusion was: according to the 2015 edition of China Pharmacopoeia, it was inconsistent with the control and did not meet the requirements.

　　In May 2016, the defendant Peng purchased 100 kilograms of raw materials of Peucedanum chinense, and on May 7, he processed and produced 97 kilograms of Chinese herbal pieces of Peucedanum chinense with the batch number of 160501, with the pre-sale price of 26 yuan per kilogram. On October 21, 2016, Lanzhou Food and Drug Administration made a random inspection of this batch of Radix Peucedani Chinese herbal pieces. On December 9, 2016, it was inspected by Lanzhou Food and Drug Inspection Institute, and the conclusion was: according to the 2015 edition of China Pharmacopoeia, it was inconsistent with the control and did not meet the requirements. On December 21, 2016, Lanzhou Food and Drug Administration seized the batch of Radix Peucedani decoction pieces according to law. On January 23, 2017, it was reinspected by Gansu Institute for Drug Inspection, and the conclusion was: According to the "Processing Standard of Traditional Chinese Medicine in Gansu Province (2009 Edition)", the result was Peucedanum, and the non-medicinal parts accounted for 19%, which did not meet the requirements.

　　In June 2015, the defendant Peng bought 12 kilograms of raw materials of Taxilli from Anhui Bozhou Medicinal Materials Market. On May 5, 2016, he put in 11 kilograms, produced and processed 10 kilograms of Chinese herbal pieces of Taxilli with batch number 160501, and passed the self-inspection on May 7. On October 11th, it was sold to Jilin Luwang Pharmaceutical Company with 5 kg of 13 yuan per kg; Sales to Jilin Qixingshan Pharmaceutical Co., Ltd. 3 kg, 11 yuan per kg. On May 5, 2017, Lanzhou Food and Drug Inspection Bureau made a random inspection of the Chinese herbal pieces. On May 27, 2017, it was inspected by Lanzhou Food and Drug Inspection Bureau, and the conclusion was that it was not consistent with the control and did not meet the requirements according to the 2015 edition of China Pharmacopoeia. On July 31, 2017, it was reinspected by Gansu Institute for Drug Inspection, and the conclusion was that according to China Pharmacopoeia (2015 edition), the results did not meet the requirements (with the characteristics of mistletoe).

　　On April 25, 2018, Lanzhou Food and Drug Administration organized relevant experts to identify the Inspection Report of the above-mentioned Chinese herbal pieces. The conclusion was: To determine the authenticity of this batch of drugs, it is necessary to check the production enterprise. If the enterprise has been registered and filed in our province in accordance with relevant laws and regulations, it has the qualification to produce and process "Big Leaf Rhizoma Drynariae", and it is not realized in our province. If there is no qualification to produce and process "Rhizoma Drynariae with big leaves", it is suggested to treat it as fake medicine. For Radix Peucedani with batch number 160501, the supervision unit should further check the registration of the drug manufacturer to see if it has the qualification to produce and process "hard Radix Peucedani". If it has the qualification, it is suggested to treat it as inferior drug, and urge the drug manufacturer to correct the name of the product and punish it according to the relevant provisions of GMP/GSP. If there is no qualification, and because "Peucedanum rigidum" belongs to the variety recorded in the standard of traditional Chinese medicine in Gansu Province, the enterprise is beyond the scope of processing and operation, it will be handled in accordance with the relevant provisions of GMP. Taxilli with batch number 160501 is suggested to be treated as fake medicine.

　　On October 11, 2019, Gansu Provincial Drug Administration replied to the questions involved in this case: (1) Yalan Pharmaceutical Co., Ltd. has the production qualification for the production of Chinese herbal pieces of Rhizoma Drynariae, Radix Peucedani and Herba Taxilli. Drynaria macrophylla was not included in Pharmacopoeia of China (2015 edition), Processing Standard of Traditional Chinese Medicine in Gansu Province (2009 edition) and Standard of Traditional Chinese Medicine in Gansu Province (2009 edition). (2) Gansu Institute of Drug Inspection found that the results of Chinese herbal medicine Qianhu were "hard Qianhu", which was recorded in Gansu Province Chinese Medicine Processing Standard (2009 edition) and Gansu Province Chinese Herbal Medicine Standard (2009 edition), and can be used instead of Qianhu in hospitals, pharmacies and other dispensing departments and retail pharmacies in our province. Does not belong to the current "Drug Administration Law of People’s Republic of China (PRC)" Article 48, paragraph 2, item 2, of the situation of passing off other drugs as such drugs. Gansu Provincial Institute of Drug Inspection found that Taxilli, a traditional Chinese medicine decoction piece, has the characteristics of mistletoe, which belongs to the situation that other drugs are passed off as this drug as stipulated in Item 2, Paragraph 2, Article 48 of the Drug Administration Law of People’s Republic of China (PRC). Viscum mistletoe is also recorded in China Pharmacopoeia (2015 edition), and its "function and indication" are consistent with those of Taxilli, so it is interoperable in clinical use.

　　The above facts were confirmed by the following evidence:

　　(1) Documentary evidence

　　1. The source of the case, the transfer of suspected criminal cases by Lanzhou Food and Drug Administration, the brief introduction of the case, and the notice of case transfer review by Lanzhou Public Security Bureau confirmed that on March 8, 2017, Lanzhou Food and Drug Administration transferred the case that Yalan Pharmaceutical Company was suspected of producing and selling fake Chinese herbal pieces of Qianhu and Rhizoma Drynariae to Yuzhong County Public Security Bureau; On November 9, 2017, Lanzhou Public Security Bureau transferred the case that Yalan Pharmaceutical Company was suspected of producing and selling fake medicine Taxilli to Yuzhong County Public Security Bureau.

　　2. The business license, organization code certificate, drug production license, trademark registration certificate, tax registration certificate, license for purchasing Chinese herbal medicines exclusively, customs declaration registration certificate of consignor and consignor of import and export goods, and drug GMP certificate of Yalan Pharmaceutical Company confirm that Yalan Pharmaceutical Company is a legally registered company with the organization code of 74589002-8, which is a member of China Commodity Bar Code System, engaged in purchasing Chinese herbal medicines, and allowed to produce Chinese herbal medicines and medicines with Chinese herbal medicines.

　　3. The notice of appointment of Yalan Pharmaceutical Company confirmed that Peng was appointed as the marketing director of the sales management center of Yalan Pharmaceutical Company on March 25th, 2015.

　　4. The production record, sales list, acceptance receipt of Gansu Longyou Pharmaceutical Logistics Co., Ltd. and sampling flow of traditional Chinese medicine decoction pieces of Yalan Pharmaceutical Company confirmed that on February 8, 2014, Yalan Pharmaceutical Company produced 3 kg of cannon bone fragments with batch number of 140201. On April 14th, 2015, Yalan Pharmaceutical Co., Ltd. produced 3 kilograms of Rhizoma Drynariae with batch number of 140201 and sold it to Gansu Longyou Pharmaceutical Logistics Co., Ltd. at the price of 28 yuan per kilogram. On May 7, 2016, Yalan Pharmaceutical Co., Ltd. produced 97 kg of Radix Peucedani with batch number 160501. On May 5, 2016, Yalan Pharmaceutical Company produced 10 kilograms of Taxilli with batch number 160501, which was sold to Jilin Luwang Pharmaceutical Co., Ltd. on October 11, 2016 with 5 kilograms of 13 yuan per kilogram, and on November 15, 2016, it was sold to Jilin Qixingshan Pharmaceutical Co., Ltd. with 3 kilograms of 11 yuan per kilogram.

　　5. The inspection report of Yalan Pharmaceutical Co., Ltd. confirmed that on February 18th, 2014, the company made a self-inspection of the production batch No.140201, and the results met the requirements according to the China Pharmacopoeia 2010. On May 7, 2016, the company conducted a self-inspection on the Peucedanum chinense with the batch number of 160501, and the results met the requirements. On May 5, 2016, the company carried out a self-inspection of Taxilli parasitica with the production batch number of 160501. The results showed that this product was tested according to the China Pharmacopoeia (2015 edition), and the results met the requirements.

　　6. Receipt confirmation: On January 10th, 2014, Yalan Pharmaceutical Company purchased 3.2kg of Rhizoma Drynariae from Ma, and the unit price was 20 yuan. On June 6th, 2015, Yalan Pharmaceutical Company purchased 12kg of Taxilli at a certain place in Cheng, and the unit price was 10 yuan.

　　7. The written decision of administrative punishment and the receipt of fines and confiscations from Lanzhou Chengguan Food and Drug Administration confirmed that on July 18th, 2016, Lanzhou Chengguan Food and Drug Administration purchased the inferior medicine of bone fracture and tonic from Yalan Pharmaceutical Company for Gansu Longyou Pharmaceutical Logistics Co., Ltd. for sale. An administrative penalty of 362.7 yuan was imposed, and the company has paid the fine.

　　(2) Testimony of witnesses

　　1. The testimony of Chang (the marketing staff of Yalan Pharmaceutical Company) and Dong (the sales department of Yalan Pharmaceutical Company) confirmed that Peng was mainly responsible for the procurement and production of raw materials for marketing three Chinese herbal medicines and the sales of finished Chinese herbal pieces. The main work of the sales department is the processing and sales of Chinese herbal pieces. Our department is fully responsible for the procurement, production and sales of Chinese herbal medicines, and the quality of finished Chinese herbal medicines is inspected by the company’s quality assurance department. Sales department 3 produces and sells according to the order. After receiving the order, raw materials are purchased first, and the raw materials are processed after passing the quality inspection. On October 21, 2016, Lanzhou Food and Drug Administration randomly sampled one kilogram of finished Peucedanum praeruptorum, which was found to be inconsistent with the provisions of the National Pharmacopoeia and was suspected of producing counterfeit drugs. Later, it was sent to Gansu Provincial Institute for Drug Control, and this batch of Chinese medicinal materials of Peucedanum praeruptorum did not meet the processing specifications of Chinese medicinal materials in Gansu, and was characterized as hard Peucedanum praeruptorum. Traditional Chinese medicine for Rhizoma Drynariae was found by Lanzhou Food and Drug Administration from Gansu Longyou Pharmaceutical Logistics Co., Ltd. to be non-compliant, and was later tested by Lanzhou Food and Drug Inspection Institute, which did not meet the requirements of China Pharmacopoeia. These two batches of drugs all passed the self-inspection.

　　2、杨某(甘肃陇邮医药物流股份有限公司采购总监)的证言证实：2015年4月16日，甘肃陇邮医药物流股份有限公司从亚兰药业公司采购了一批次的骨碎补中药材，批号是140201，总共3公斤，采购价是84元，这批中药材是经亚兰药业检验合格才采购的，最后分发给公司下属的药店销售。兰州市城关区食药局2015年6月26日抽检了该批中药材，检验报告是不符合规定，2016年7月14日对甘肃陇邮医药物流股份有限公司作出行政处罚。2015年10月接到检验报告后甘肃陇邮医药物流股份有限公司对该批药品召回处理。

　　3. The testimony of Zhang (the person in charge of quality assurance department of Yalan Pharmaceutical Company) confirmed that Yalan Pharmaceutical Company started the inspection according to the standard of China Pharmacopoeia from the purchase of raw materials, and then entered the next production link after passing the inspection. After being processed into Chinese herbal pieces, the finished products were inspected, and the batches of drugs were sampled according to the standard for inspection, which was divided into factory inspection and factory inspection. The peucedanum and hard peucedanum sampled by Yalan Pharmaceutical Company are sold only after passing the self-inspection by their own quality inspection department.

　　4. The testimony of Li (general manager of Yalan Pharmaceutical Co., Ltd.) confirmed that Peng’s third marketing department took office on March 25, 2015. Mainly responsible for the procurement, production and product sales of raw materials. He is solely responsible for the procurement, production and sales of Chinese herbal medicines, and is responsible for all the affairs of Chinese herbal medicines in the company according to the needs of production. If there are any problems with the procurement, processing and sales of Chinese herbal medicines, he is entirely responsible for them, and the quality of finished Chinese herbal medicines is inspected by the quality assurance department of the company. The raw materials of parasitic loranthus that failed the sampling inspection were purchased by the department in charge of Peng, and all the medicines passed the self-inspection.

　　(3) Appraisal opinions

　　1. The drug inspection report of Lanzhou Food and Drug Inspection Institute confirmed: On October 12, 2015, the Rhizoma Drynariae (Canned Rhizoma Drynariae) with batch number of 140201 produced by Yalan Pharmaceutical Company was inspected, and there were two large vascular bundles in the center of about 62% of the section, which were crescent-shaped, which did not meet the requirements; The thin-layer chromatography is inconsistent with the control and does not conform to the regulations. Conclusion: This product was tested according to China Pharmacopoeia (2010 edition), and the results did not meet the requirements.

On December 9, 2016, the Peucedanum Peucedanum with batch number 160501 produced by Yalan Pharmaceutical Company was tested, and the conclusion was that this product was tested according to China Pharmacopoeia 2015, which was inconsistent with the control, and the result did not meet the requirements. On May 5, 2017, the batch number of Taxilli parasitica produced by Yalan Pharmaceutical Company was 160501, and the conclusion was that this product was tested according to China Pharmacopoeia 2015, which was inconsistent with the control and the result did not meet the requirements.

　　2. The inspection report of Gansu Institute of Drug Inspection confirmed that on January 23, 2017, the Peucedanum praeruptorum with batch number of 160501 produced by Yalan Pharmaceutical Company was reinspected, and the conclusion was that this product was tested according to the Standard for Processing Traditional Chinese Medicine in Gansu Province (2009 edition), and the conclusion was that Peucedanum praeruptorum was hard, with non-medicinal parts accounting for 19%, which did not meet the requirements. On July 31st, 2017, the batch number of Taxilli produced by Yalan Pharmaceutical Company was 160501, and the conclusion was: according to China Pharmacopoeia 2015, the results did not meet the requirements (with the characteristics of mistletoe).

　　3. Lanzhou Food and Drug Administration’s reply to the Application for Identification of Chinese Herbal Pieces such as Rhubarb confirmed that on April 25, 2018, the bureau set up a "Drug Identification Expert Database" and organized relevant experts to identify the Inspection Report of Chinese Herbal Pieces such as Rhubarb. The conclusion is that the batch number of Rhizoma Drynariae is 140201, and the manufacturer needs to be verified to determine the authenticity of this batch of drugs. If the enterprise has been registered and put on record in our province in accordance with relevant laws and regulations, has the qualification to produce and process "Daye Rhizoma Drynariae", and has been produced, processed and transshipped in our province, but it has not been corrected, it will be handled in accordance with the relevant provisions of GMP/GSP. If there is no qualification to produce and process "Rhizoma Drynariae with big leaves", it is suggested to treat it as fake medicine. For Radix Peucedani with batch number 160501, the supervision unit should further check the registration of the drug manufacturer to see if it has the qualification to produce and process "hard Radix Peucedani". If it has the qualification, it is suggested to treat it as inferior drug, and urge the drug manufacturer to correct the name of the product and punish it according to the relevant provisions of GMP/GSP. If there is no qualification, and because "Peucedanum rigidum" belongs to the variety recorded in the standard of traditional Chinese medicine in Gansu Province, the enterprise is beyond the scope of processing and operation, it will be handled in accordance with the relevant provisions of GMP. Taxilli with batch number 160501 is suggested to be treated as fake medicine.

　　4. The reply from Gansu Provincial Drug Administration confirmed that: (1) Yalan Pharmaceutical Company has the production qualification to produce Chinese herbal pieces of Rhizoma Drynariae, Radix Peucedani and Herba Taxilli. Drynaria macrophylla was not included in Pharmacopoeia of China (2015 edition), Processing Standard of Traditional Chinese Medicine in Gansu Province (2009 edition) and Standard of Traditional Chinese Medicine in Gansu Province (2009 edition). (2) Gansu Institute of Drug Inspection found that the results of Chinese herbal medicine Qianhu were "hard Qianhu", which was recorded in Gansu Province Chinese Medicine Processing Standard (2009 edition) and Gansu Province Chinese Herbal Medicine Standard (2009 edition), and can be used instead of Qianhu in hospitals, pharmacies and other dispensing departments and retail pharmacies in our province. Does not belong to the current "Drug Administration Law of People’s Republic of China (PRC)" Article 48, paragraph 2, item 2, of the situation of passing off other drugs as such drugs. Gansu Provincial Institute of Drug Inspection found that Taxilli, a traditional Chinese medicine decoction piece, has the characteristics of mistletoe, which belongs to the situation that other drugs are passed off as this drug as stipulated in Item 2, Paragraph 2, Article 48 of the Drug Administration Law of People’s Republic of China (PRC). Viscum mistletoe is also recorded in China Pharmacopoeia (2015 edition), and its function and indications are consistent with those of Taxilli, so it is interoperable in clinical use.

　　(4) transcripts of on-site inquests and inspections

　　Records of on-site inspection and photos, and records of seizure and detention confirmed that Lanzhou Food and Drug Administration inspected the drugs produced by Gansu Yalan Company, and seized and detained Rhizoma Drynariae, Radix Peucedani and Herba Taxilli.

　　(5) confessions of the defendant

　　The confession of the defendant Peng confirmed: I am responsible for the acquisition, processing and sales of Chinese herbal medicines in Yalan Pharmaceutical Company, and now I am the sales manager of the company. At the end of 2016, Lanzhou Food and Drug Administration randomly sampled the Chinese herbal medicines Rhizoma Drynariae and Radix Peucedani produced by our unit. The Radix Peucedani was tested by Lanzhou Food and Drug Inspection Institute according to China Pharmacopoeia (the first part of 2015 edition), and the conclusion was inconsistent with the control and did not meet the requirements. After the re-inspection by Gansu Institute for Drug Inspection, according to the Standard for Processing Traditional Chinese Medicine in Gansu Province (2009 edition), it was determined that the Chinese herbal medicine produced by our company was Peucedanum rigidum, and the non-medicinal part accounted for 19%, which did not meet the requirements. Peucedanum praeruptorum is a standard term collected in China Pharmacopoeia. Peucedanum praeruptorum is produced in Gansu Province, mainly because of its different characters, but Peucedanum praeruptorum conforms to the standard of Gansu Province’s Processing Standard of Traditional Chinese Medicine (2009 edition). Peucedanum praeruptorum used in this batch of products of our company conforms to the standard of Gansu Province, and 19% of it refers to the stem of Peucedanum praeruptorum. I know that the stem of Peucedanum Peucedanum is a non-medicinal part, which is considered as an impurity in the standard of processing decoction pieces, but we control it within the allowable range. In March 2016, I bought the raw materials of Peucedanum in Hebei Anguo Medicinal Materials Market, with a total of 100 kilograms per kilogram of 20 yuan. On May 7th, 2016, it was produced and processed into 97kg of Chinese medicinal materials of Radix Peucedani. This batch of medicine was produced according to the company’s production plan. The batch number of this batch of medicine was 160501, and the cost price was 26 yuan per kilogram. Now it is not sold, and it was detained by Lanzhou Food and Drug Administration in the company’s warehouse.Our company’s Rhizoma Drynariae was tested according to the standard of China Pharmacopoeia (2015 edition), and the results did not meet the requirements. Drynaria fortunei was put into production by our company on February 8, 2014. The original medicinal materials were purchased from the Yellow River Market in Lanzhou. At that time, 3.2 kilograms of the original medicinal materials were purchased, and 3 kilograms of the finished Chinese medicinal materials were processed and produced. The batch number was 140201. These 3 kilograms of Chinese medicinal materials were wholesale to Gansu Longyou Pharmaceutical Logistics Co., Ltd., with a total of 84 yuan per kilogram of 28 yuan. The raw materials of Taxilli parasitica produced and sold by our company were purchased in June 2015 in Haozhou, Anhui Province, with a total purchase of 12kg at the unit price of 10 yuan. On May 5th, 2016, 11kg of raw materials were put in, and processed into 10kg of Chinese herbal pieces. On May 7th, the quality inspection department of our unit passed the self-inspection and released for sale. On October 11th, it sold 5kg of 13 yuan to Jilin Luwang Pharmaceutical Co., Ltd., and on November 15th, it sold 3kg of 11 yuan to Jilin Qixingshan Pharmaceutical Co., Ltd. This year, the Food and Drug Administration sampled 1kg, and now there is 1kg left in stock. The batch number of this batch of Herba Taxilli Chinese herbal pieces is 160501. Inspection by Lanzhou Food and Drug Inspection Institute and re-inspection by Gansu Institute of Drug Inspection showed that the batch number of Chinese traditional medicine decoction pieces of Herba Taxilli produced by our unit was 160501, and the re-inspection results showed that it had the characteristics of mistletoe. I can’t tell the difference between mistletoe and mistletoe, both of which are used medicinal materials. They were originally called mistletoe, and their functions and effects are the same. They are harmless to human body and cannot be distinguished by naked eyes.I am responsible for purchasing all the raw materials for the production of traditional Chinese medicine, and our company has inspected them before releasing them after passing the self-inspection.

　　The court of first instance held that the defendant, Yalan Pharmaceutical Company, had violated the national drug administration laws and regulations by producing and selling counterfeit drugs, which had violated the criminal law and constituted the crime of producing and selling counterfeit drugs, and should be punished according to law. The accusation by the public prosecution agency that the batch number 140201 of Rhizoma Drynariae and the batch number 160501 of Herba Taxilli produced and sold by Yalan Pharmaceutical Company are counterfeit drugs, the facts are clear, the evidence is true and sufficient, and the charges are established, which should be supported. The accusation of the public prosecution agency that the batch number of Qianhu Chinese medicine decoction pieces produced by Yalan Pharmaceutical Company is 160501 is counterfeit is not supported because of insufficient evidence. Defendant Peng, as the head of the third marketing department of Yalan Pharmaceutical Company, is the person directly responsible for purchasing, processing and selling the raw materials of the two batches of Chinese herbal medicines, namely Rhizoma Drynariae and Herba Taxilli, and should be convicted and punished for the crime of producing and selling counterfeit drugs. In view of the fact that the number of fake medicines produced by the defendant unit is small, the description of fake medicine Taxilli is consistent with that of mistletoe, and there is interoperability in clinical use, so the circumstances of the crime are minor, and the defendant unit Yalan Pharmaceutical Company and the defendant Peng Mou can be given a lighter punishment according to law. According to the provisions of Articles 141, 150, 30, 31, 52, 53, 72, 1 and 3, and 73, 1 and 3 of the Criminal Law of People’s Republic of China (PRC), the defendant Gansu Yalan Pharmaceutical Co., Ltd. was convicted of producing and selling counterfeit drugs and fined 10,000 yuan; The defendant Peng was convicted of producing and selling counterfeit drugs and sentenced to six months in criminal detention.Suspended for ten months and fined 5000 yuan.

　　The appellate unit Yalan Pharmaceutical Company and its defenders put forward that the court of first instance decided that Rhizoma Drynariae was a counterfeit drug on the basis of the inspection report issued by Lanzhou Food and Drug Inspection Institute, and the inspection method adopted in this appraisal opinion was wrong, which led to the wrong appraisal conclusion; "Mistletoe" and "Taxilli" are difficult to distinguish in reality, which leads to the company’s inability to distinguish from the purchase to the identification. The company did not intentionally produce counterfeit drugs, and the social harm was not great, so it could not be recognized as counterfeit drugs. It requested to revoke the first-instance judgment and change the verdict to innocence.

　　Appellant Peng proposed that the conclusion of the appraisal opinion of the cannon bone fragments identified by the court of first instance was wrong, and the inspection method on which the appraisal opinion was based was wrong, so the cannon bone fragments involved should not be identified as counterfeit drugs; Because it is difficult to distinguish mistletoe from mistletoe in reality, there is a wrong understanding, and there is no intention to produce and sell counterfeit drugs subjectively; In this case, it is only responsible for purchasing, and the main responsibility should be borne by the quality assurance department; In the whole case, the circumstances are obviously minor, and the harm is not great. As the person in charge of drug procurement, processing and sales, he should not be considered as other directly responsible personnel, and requested to revoke the judgment of first instance and change his sentence to innocence.

　　Defender of Appellant Peng proposed: The basis for the first instance to determine that the batch number of the Chinese herbal pieces of Cannabis Rhizoma Drynariae with batch number of 140201 belongs to counterfeit drugs, that is, there are contradictory appraisal opinions, which is a fact finding error; The appellant did not have the subjective intention to produce and sell "Taxilli" as "Mistletoe", which did not constitute the crime of producing and selling counterfeit drugs; It is doubtful whether this case meets the prosecution standard of the crime of producing and selling counterfeit drugs.

　　The court found that the original judgment found that the appellant Yalan Pharmaceutical Company and the appellant Peng had committed the crime of producing and selling counterfeit drugs, and the evidence was true and sufficient. The listed evidence had been publicly presented, cross-examined and certified in the court of first instance. The court confirmed the facts and evidence found in the first instance according to law, and no new evidence was submitted by the appellant, appellant and defender in the second instance.

　　The appraisal opinions of the appellate unit, the appellant and the defender that the court of first instance identified counterfeit drugs are the reasons for appeal and defense opinions that the inspection method is wrong and cannot be used as the basis for finalizing the case. After investigation, Lanzhou Food and Drug Inspection Institute is a specialized inspection institution with drug inspection qualification. The LZ2015Y2363 inspection report issued by it shows that the inspection result of Rhizoma Drynariae with the batch number of 140201 is not in conformity with the regulations. In view of this inspection report, the appellant did not apply for re-inspection within the effective period, so the inspection result should be considered valid. Lanzhou Food and Drug Administration’s reply to the Application for Identification of Chinese Herbal Pieces such as Rhubarb indicated that the manufacturer of Rhizoma Drynariae (batch No.140201) needs to be verified in order to judge the authenticity of this batch of drugs. If the company has been registered in our province in accordance with relevant laws and regulations, it has the qualification to produce and process Rhizoma Drynariae with big leaves, but it has not been corrected in our province, it will be in accordance with GMP/GSP. If there is no qualification to produce and process "Rhizoma Drynariae with big leaves", it is suggested to treat it as fake medicine. According to the reply of Gansu Drug Administration on this case, Gansu Yalan Pharmaceutical Co., Ltd., the appellant, has the production qualification to produce pieces of Rhizoma Drynariae, and "Rhizoma Drynariae with big leaves" has not been included in China Pharmacopoeia, Gansu Province Chinese Medicine Processing Standard and Gansu Province Chinese Medicine Standard. According to the second paragraph of Article 141 of the Criminal Law, whether it is a counterfeit drug shall be subject to the Drug Administration Law of People’s Republic of China (PRC), and according to the relevant provisions of this law,Chinese herbal pieces must be produced in accordance with the national drug standards and the production technology approved by the drug supervision and administration department of the State Council. If there are no provisions in the national drug standards, they must be processed in accordance with the processing standards formulated by the drug supervision and administration departments of the people’s governments of provinces, autonomous regions and municipalities directly under the Central Government. Drynaria macrophylla is not included in China Pharmacopoeia, Gansu Chinese Medicine Processing Standard and Gansu Chinese Medicine Standard. Therefore, Drynaria macrophylla is not a drug prescribed by the state, and the production and sale of Drynaria macrophylla is a fake drug, which is a non-drug or another drug. Therefore, the appeal reason and the defense opinion put forward by the appellant and the appellant cannot be established.

　　As for the appeal unit, the appellant and the defender, it is difficult to distinguish mistletoe and Taxilli because of reality, and there is no subjective and intentional appeal reason and defense opinion for producing and selling counterfeit drugs. After investigation, the drug inspection report of Lanzhou Food and Drug Inspection Institute and the inspection report of Gansu Drug Inspection Institute confirmed that the "Taxilli" with batch number of 160501 did not meet the requirements, and it had the characteristics of "mistletoe", which belonged to the situation that other drugs passed off as this drug. According to the People’s Republic of China (PRC) Pharmacopoeia, there was a certain difference between "mistletoe" and "Taxilli", indicating that there was an objective possibility to distinguish them. In this case, the Appellant and the Appellant, as professional organizations and personnel with professional knowledge, should have the ability to distinguish between mistletoe and Taxilli, and their inability to distinguish between mistletoe and Taxilli as the subjective and intentional appeal reason and defender for not producing and selling counterfeit drugs cannot be established.

　　Appeal reasons and defense opinions of the appellant and the defender that the case does not meet the prosecution standard for the crime of producing and selling counterfeit drugs, and that the circumstances of the crime are obviously minor and the harm is not great, so it is not suitable for criminal treatment. After investigation, after the implementation of the Criminal Law Amendment (VIII) of People’s Republic of China (PRC), the constitutive elements of the crime of producing and selling counterfeit drugs are no longer required to be "harmful to human body". As a professional, there have been many irregular purchases and sales, and their actions have endangered public health. The actions of the appellant and the appellant have constituted the crime of producing and selling counterfeit drugs and should be punished according to the Criminal Law. The court of first instance combined the criminal motives, subjective intention, objective behavior and social harmfulness of the two appellants, and made a judgment, which was given a lighter sentence within the statutory penalty range, which was an appropriate sentence. Therefore, the appeal reason and the defender’s defense opinion could not be established.

　　As the person in charge of drug procurement, processing and sales mentioned by the appellant Peng and his defenders, it should not be regarded as the appeal grounds and defense opinions of other directly responsible personnel. After investigation, according to the documents of Gansu Yalan Pharmaceutical Co., Ltd., witness testimony and Peng’s confession, Peng, as the director of the marketing department of the sales management center, is responsible for the procurement, processing and sales of raw materials of the department, and is responsible for the supervision and management of the drugs produced and sold. As the directly responsible person in charge, Peng should bear corresponding criminal responsibilities. The grounds for appeal cannot be established.

　　We believe that the facts of the original judgment that the appellant Gansu Yalan Pharmaceutical Co., Ltd. and the appellant Peng Mou committed the crime of producing and selling counterfeit drugs are clear, the evidence is indeed sufficient, the applicable law is correct, the sentencing is appropriate, and the trial procedure is legal. In accordance with the provisions of Article 236, Paragraph 1 (1) and Article 244 of the Criminal Procedure Law of People’s Republic of China (PRC), the ruling is as follows:

　　Reject the appeal and uphold the original judgment.

　　This ruling is final.

　　Presiding judge Zhao Jinrong

　　Judge An Hairong

　　Judge Song Ximin

　　February 25, 2020

　　Judge? Assistant Zhu Yiming

　　Clerk Ren Zixuan

Shengming: This article is reproduced for the purpose of transmitting more information. If the source is marked incorrectly or infringes on your legitimate rights and interests, please contact this website with the ownership certificate, and we will correct and delete it in time. Thank you. Tel: 028-60185688, email: kefu@zyctd.com.

Machine heart report

Editor: Chen Ping, Devil

The training of deep learning model is like "black box operation", knowing what the input is and what the output is, but the intermediate process is like a black box, which makes researchers spend a lot of time to find out why the model is not working properly. It would be great if there is a visual tool that can help researchers better understand the model behavior.

Recently, Google researchers released a language interpretability tool (LIT), which is an open source platform for visualizing and understanding natural language processing models.

Address: https://arxiv.org/pdf/2008.05122.pdf.

Project address: https://github.com/PAIR-code/lit.

LIT focuses on the core issues of model behavior, including: Why does the model make such predictions? When is the performance poor? What happens when the input changes are controllable? LIT integrates local interpretation, aggregation analysis and counterfactual generation into a streamlined browser-based interface to realize rapid exploration and error analysis.

This study supports a variety of natural language processing tasks, including exploring the counterfactual of emotional analysis, measuring gender bias in the coreference system, and exploring local behaviors in text generation.

In addition, LIT also supports a variety of models, including classification, seq2seq and structured prediction models. And it is highly extensible and can be extended through declarative and framework-independent API.

For related demo, see the video:

It can be reconfigured for novel workflow, and these components are independent, portable and easy to implement.

User Interface(UI)

LIT is located in a single-page web application, which consists of multiple toolbars and a main part with multiple independent modules. If modules are applicable to the current model and data set, they will be displayed automatically. For example, the module that displays the classification results is only displayed when the model returns MulticlassPreds.

LIT user interface

The layout design of LIT.

function

LIT supports various debugging workflows through a browser-based user interface (UI). Functions include:

Local interpretation: it is carried out through the saliency map, attention map and rich visualization map predicted by the model.

Aggregation analysis: including user-defined metrics, slicing and binning, and visualization of embedded space.

Counterfactual generation: create and evaluate new examples dynamically by manually editing or generating plug-ins for counterfactual reasoning.

Side-by-side mode: Compare two or more models, or one model based on a pair of examples.

Highly extensible: it can be extended to new model types, including classification, regression, span labeling, seq2seq and language modeling.

Frame-independent: compatible with TensorFlow, PyTorch, etc.

Let’s look at several main modules of LIT:

Exploring data sets: Users can interactively explore data sets using different standards across modules (such as data tables and embedded modules), thus rotating, scaling and translating PCA or UMAP projections to explore clusters and global structures.

Compare models: By loading multiple models in the global settings control, LIT can compare them. Then copy the submodule that displays the information of each model to facilitate the comparison between the two models. Other modules (such as embedded module and measurement module) are updated at the same time to display the latest information of all models.

Compare datapoints: switch to the "Compare data points" button in the selection toolbar to make LIT enter the data point comparison mode. In this mode, the main data point is selected as the reference data point, and it will be used as the reference point for comparison in subsequent settings. Reference data points are highlighted in the data table with a blue border.

See: https://github.com/pair-code/lit/blob/main/docs/user _ guide.md for details of other modules.

After reading the above introduction, are you eager to get started and try this cool visualization tool? Let’s take a look at its installation process and examples.

Installation tutorial

Download the software package and configure Python environment. The code is as follows:

git clone https://github.com/PAIR-code/lit.git ~/lit# Set up Python environmentcd ~/ litconda env create -f environment.ymlconda activate lit-nlpconda install cudnn cupti # optional, for GPU supportconda install -c pytorch pytorch # optional, for PyTorch# Build the frontendcd ~/lit/lit_nlp/clientyarn && yarn build

After installing and configuring the environment, you can experience the examples included in the toolkit.

example

1. Example of emotional classification

The code is as follows:

cd ~/litpython -m lit_nlp.examples.quickstart_sst_demo –port=5432

The example of emotion classification is a fine-tuned BERT-tiny model based on Stanford Emotion Tree Library, which can be completed in less than 5 minutes on GPU. After the training is completed, it will start the LIT server on the development set.

2. Language modeling class example

To explore the prediction results of the pre-training model (BERT or GPT-2), run the following code:

cd ~/litpython -m lit_nlp.examples.pretrained_lm_demo –models=bert-base-uncased –port=5432

For more examples, please refer to the directory: /lit_nlp/examples.

In addition, the project also provides a way to add your own models and data. By creating a customized demo.py launcher, users can easily run LIT with their own models, similar to the above sample directory /lit_nlp/examples.

See: https://github.com/pair-code/lit/blob/main/docs/python _ api.md # adding-models-and-data for the complete adding process.

Reference link:

http://www.iibrand.com/news/202008/1719096.html

https://github.com/PAIR-code/lit/blob/main/docs/user_guide.md

https://github.com/PAIR-code/lit/blob/main/docs/python_api.md#adding-models-and-data

https://medium.com/syncedreview/google-introduces-nlp-model-understanding-tool-ab840b456be3

Amazon SageMaker is a fully hosted service that can help developers and data scientists quickly build, train and deploy machine learning models. SageMaker completely eliminates the heavy work of each step in the machine learning process, making it easier to develop high-quality models.

Now, enterprise developers can get 1000 yuan service vouchers for free, easily get started with Amazon SageMaker, and quickly experience five examples of artificial intelligence applications.

? THE END

Please contact Ben WeChat official account for authorization.

Contribute or seek reports: content@jiqizhixin.com.

Original title: "LIT, Google Open Source NLP Model Visualizer, Model Training is no longer a" black box ""

Read the original text

Justice League

DC and Marvel Comics will finally be "positive" in the mainland market this year.

The release of "Batman v Superman: Dawn of Justice" in 2016 officially announced the opening of the DC movie universe, and the official also announced that many independent superhero works will be put into shooting. The commercial purpose of accelerating the expansion of the film universe is undoubtedly Marvel Comics, which is in full swing and monopolizes the super-British film market.

Judging from the trend in the past two years, DC released three works of Bat Chao almost at the same frequency as Marvel Comics, but the schedule of the mainland and the works of Marvel Comics released at the same time were staggered for more than a month.

Captain America: Civil War May 6, 2016 & mdash; — Batman v Superman: Dawn of Justice, March 25th, 2016.

Galaxy Guard 2, May 5, 2017 & mdash; — Wonder Woman, June 2, 2017

Thor: Ragnarok, November 3, 2017 & mdash; — Justice League November 17, 2017

Until today’s simultaneous release in China (hereinafter referred to as "Zhenglian"), the domestic audience finally waited for DC and Marvel Comics to look back.　

As DC’s first "superhero group" work, it is only less than two weeks away from Marvel Comics’s Thor: Ragnarok release. When two topical works meet, it’s hard for the audience not to compare which is better or worse, and fans in Marvel Comics and DC at home and abroad also started fighting on social media early. However, the staff of the two companies hold an inclusive attitude towards such healthy competition.

　James gunn, director of "Silver Guard" series, admits that he actually likes DC’s works very much.

　President Marvel Comics came out to "persuade the fans"

　Goddess Gado said in an interview that she likes Marvel Comics’s works.

　"Super Super" Henry Cavill: The roles of both sides should be respected.

So, as a loyal fan of superhero movies, Xiao Bian advises you: there is no need to compare too much. After all, there is no distinction between high and low justice.

Judging from the style of Bat Chao, every key work of DC must be full of eggs, and it is also painstaking to pave the way for future works and accumulate popularity. After watching the movie at the first time, Xiaobian summed up these small details that you got or didn’t get. From the numerous hints given by the government, we can even see the story trend of the future DC movie universe.

1 "Maybe more than six chairs"

Justice League has a large number.

Although all kinds of materials advertised in the new film are all under the banner of the Big Five, fortunately, our "Super Super" has officially come back in Zhenglian. With the growth of DCEU, as the female Xia said at the end of the story when the master designed the headquarters of Zhenglian, "Maybe there are more than six chairs". Obviously, this line is intentional by the screenwriter, which implies that more new members will join the Justice League in the future. So who will it be?

The Justice League in the cartoon has as many people as The Avengers in Marvel Comics. However, once it is made into a movie, the number of places will be limited, and the film side has no energy to take care of so many super English. Therefore, if you want to come first, it is hoped that these people will join first from the new work.

— — Green Lantern

Green Lantern

After Ryan Reynolds’s success in Marvel Comics’s "Deadpool", DC must be even more upset about the double loss of popularity of the old version of "The Green Lantern" starring him, so he put the shooting plan of "The Green Lantern Corps" on the agenda early. In Zheng Lian, the green light warrior also appeared in the first invasion of the earth by the wild wolf: in the human phalanx that fought back against Parademons’s army, it was the early green light man who used the green ring to fight.

　

Green Lantern Corps

The difference between the Green Lantern and other superheroes is that the title of "Green Lantern" refers not only to a certain person, but to a group. In the Green Lantern Corps, every soldier wears an energy ring, and the intensity of the energy released depends on the willpower of the soldier himself. It can be said that it is a super weapon without an upper limit. Therefore, with this power, the Green Lantern can naturally rank among the Zhenglian.

— — Shazam

In the ancient war, do you remember the strong man who released lightning with his hands? He is wonder woman’s father Zeus.

Although the Greek gods only appeared in ancient times, some people in the Orthodox League also inherited their abilities, that is, the superhero Shazam, who has exposed that he is about to make a film version.

　

Comic editionShazam

"Shazam" is the title of wizards who fight evil, which has been handed down from generation to generation. The man who fought in the first invasion of the Wilderness Wolf was probably the earliest wizard in history, that is, the first person to use the name "Shazam". The wizard signed a contract with the gods and was given the powerful magical power of the Greek gods. He can also release magic lightning like Zeus.

According to foreign media rumors, the first Shazam of DC will be played by Zachary Levi (this brother also played Thor: Ragnarok & HELLIP; … )

　

Zachary Levi

But his old enemy "Black Adam" — — As a wizard with the same magical power as Shazam, this villain will be played by the actor "Boulder" Qiang Sen, who is extremely popular in recent years.

(The picture shows netizens making their own, unofficial)

Next page: Flash’s parents

　　Editor’s Note: The report of the 19th National Congress of the Communist Party of China put forward the general requirements for Party building in the new era, and strategically pointed out the direction of Party building in the new era. What kind of party should we build and how to build it in the new era? The general requirements put forward the purpose, policy, main line, overall layout and objectives of party building in the new era. Qiushi. com plans to launch a special topic to deeply interpret the specific contents of these five aspects and their relationships for you. Let’s look at them together ↓ ↓

　　1. What are the five basic connotations of the general requirements?

　　1. Purpose: To uphold and strengthen the overall leadership of the Party.

　　At the beginning of the general requirements, it is clearly stated that we should "uphold and strengthen the overall leadership of the Party" and point out the purpose and fundamental principles of Party building in the new era. Party leadership is the "anchor needle" to overcome all difficulties and risks, and it must be comprehensive and holistic. Any field, aspect and link that is missing or weakened will weaken the Party’s strength and harm the cause of the Party and the people.

　　2. Guiding principle: Adhere to the Party’s management of the Party and strictly manage the Party in an all-round way.

　　The general requirements specify the guiding principle of Party building, that is, "Insist on the Party’s management of the Party and strictly manage the Party in an all-round way", and that "China’s problems will come from within communist party". If the Party’s management is weak and lax, the Party will inevitably be eliminated by history and its historical mission will not be realized.

　　3. Main line: Strengthen the construction of the Party’s long-term ruling ability, advancement and purity.

　　The general requirements put forward that "strengthening the construction of the Party’s long-term ruling ability, progressiveness and purity is the main line", which profoundly shows that improving the Party’s ruling ability and leadership level and maintaining the Party’s advanced and purity will always be on the road, which will inevitably accompany the whole process of our Party’s ruling and the magnificent journey of Socialism with Chinese characteristics.

　　4. Overall layout: "5+2"

　　The general requirements further clarify the overall layout of party building, emphasizing "comprehensively promoting the party’s political construction, ideological construction, organizational construction, work style construction and discipline construction, and deepening the anti-corruption struggle through the system construction", grasping the key of party building in the new era, and highlighting the leading position of political construction and discipline construction, which is the fundamental strategy for managing the party and governing the party.

　　5. Goal: Five sentences

　　The general requirements set the party’s construction goal in the new era, that is, "to build the party into a Marxist ruling party that is always in the forefront of the times, wholeheartedly supported by the people, brave in self-revolution, able to stand the test of all kinds of storms, and full of vigor and vitality", which embodies the nature, purpose and program of the party and the value orientation, political determination and mission responsibility of the Communist Party of China (CPC) people in the new era.

　　Second, what is the relationship between the five basic connotations of the general requirements?

　　The general requirements constitute a scientific and organic whole of Party building in the new era. The purpose, policy, main line, overall layout and objectives of Party building in the new era are closely related, interactive and mutually promoting.

　　1. Purpose

　　The purpose is the basis and the fundamental point, and the party building should be carried out closely around this purpose, and it should not be separated or deviated at all times.

　　2. Policy

　　The policy is principle and compliance, which leads the party’s construction in the right direction.

　　3. Main line

　　The main line is the outline and the soul. The outline is open and the soul is here.

　　4. Overall layout

　　The overall layout is the key point and the path. When the overall layout is established, the party building will have solid support and a strong grasp.

　　5. Objectives

　　The goal is the direction and the foothold, and all the work of party building should be strengthened towards this goal and tested according to this goal.

On March 24th, the second batch of Cushing COVID-19 vaccine that China assisted the Philippines arrived in Manila, the capital of the Philippines, to help the Philippines accelerate the implementation of the COVID-19 vaccination program. Xinhua news agency

On March 30th, the COVID-19 vaccine aided by China government arrived in Addis Ababa, the capital of Ethiopia. Xinhua news agency

On April 1st, Cambodia began to vaccinate its citizens with China Kexing COVID-19 vaccine. The picture shows a woman taking the first dose of Kexing COVID-19 vaccine in Phnom Penh, Cambodia. Xinhua news agency

In recent days, China COVID-19 vaccine has been delivered to many countries and received warm welcome. China is actively fulfilling its commitment to make the new vaccine a global public product, striving to improve the accessibility and affordability of vaccines in developing countries, providing vaccine assistance to 80 countries and 3 international organizations, and exporting vaccines to more than 40 countries. Foreign governments and people have expressed their gratitude to China, believing that the vaccines provided by China are very important for fighting the epidemic, and China has made irreplaceable contributions to international cooperation in fighting the epidemic.

On the evening of April 2, the first batch of China COVID-19 vaccine purchased by the Mongolian government arrived in Ulaanbaatar, the capital of Mongolia. Speaking at the handover ceremony, Mongolian Foreign Minister Battsetseg said that during the severe period of Mongolia’s anti-epidemic, China first provided free assistance to Mongolian vaccines to provide strong support for the vaccination work of key populations in Mongolia. This time, China provided the first batch of China vaccines purchased by Mongolia in a short time, which helped Mongolia to fight the epidemic and restore its economy. Mongolia expressed its heartfelt thanks for this.

On the evening of April 1st, an Argentinean airline chartered plane arrived at the Esseza International Airport in Buenos Aires, and successfully returned the second batch of COVID-19 vaccine developed and produced by China Sinopharm Group. Argentine Health Minister Bisotti greeted him at the airport. Argentine Foreign Minister Sola posted a message on social media thanking the government of China for its assistance in vaccine cooperation between the two countries.

On March 31st, China government assisted Sri Lankan COVID-19 vaccine to arrive at Bandaranaike International Airport in Colombo, Sri Lanka, and Sri Lankan President Gotabaya Rajapaksa led several ministers to meet him at the airport. Gotabaya posted a message on social media that day, thanking the leaders of China and the people of China for giving priority to Sri Lanka in international cooperation to fight the epidemic.

On March 30th, China government assisted Ethiopian COVID-19 vaccine to arrive in its capital Addis Ababa. Ethiopian Health Minister Leah tadesse was greeted at the airport. Tadesse said in his speech that China’s aid to COVID-19’s vaccine is a powerful testimony to the strong relationship between the two countries. She said that the vaccine aided by China will greatly help Ethiopia achieve the goal of vaccination of 20% of the country’s population at an early date.

On March 29th, the COVID-19 vaccine of China Sinopharm Group, which was aided by the China government, arrived in Ramallah. Pakistani Health Minister Mayi Keira said at the handover ceremony that China’s vaccine rushed to Palestine, which provided great support and help for Pakistan to implement COVID-19’s vaccination plan. Pakistan highly appreciates China’s firm commitment to make vaccines a global public product and its selfless help to developing countries such as Palestine with a responsible attitude and practical measures.

The handover ceremony of China’s aid to Nepal’s COVID-19 vaccine was held on March 29th at the Prime Minister’s residence in Kathmandu, the capital of Nepal. Nepal’s Prime Minister Ollie expressed his heartfelt thanks to the China government for its generous donation. He said that China’s measures and efforts to fight the COVID-19 epidemic are commendable, and China’s successful experience in fighting the epidemic is worth learning from other countries.

The first batch of COVID-19 vaccine developed by China Kexing Company arrived in El Salvador on March 28th. Health Minister Francisco Arabi said that the arrival of China vaccine brought hope for El Salvador’s fight against epidemic diseases, which will help the local COVID-19 vaccination program, protect local people and help them return to normal life as soon as possible. El Salvador President Buckel expressed his gratitude to China for providing anti-epidemic support on social media the day before.

The first batch of China COVID-19 vaccine purchased by the Uzbek government arrived in Tashkent on March 27th. Uzbek Health Minister Gadzhibayev said that Uzbekistan attaches great importance to developing vaccine cooperation with China. The China COVID-19 vaccine delivered to Uzbekistan will be distributed to more than 3,000 vaccination sites in the country for mass vaccination.

A batch of COVID-19 vaccines provided free of charge by the China government and the China People’s Liberation Army to the transitional government and military of Sudan arrived in Khartoum, the capital of Sudan, on the evening of March 26th. Tabar, a member of Sudan’s Sovereignty Committee and chairman of the Supreme Committee of Health Emergency, said that China helped the Sudan as soon as it overcame difficulties, which showed the friendly relations between the two countries as close as brothers. Sudanese Health Minister Omar said that since the outbreak, China has provided many batches of assistance to the Soviet side and sent medical experts to the Soviet Union to share China’s anti-epidemic experience, and the Soviet side is grateful. Medical and health cooperation has become an indispensable part of the strategic partnership between the two countries. I believe that with the strong support of China, the Soviet side will be able to finally defeat the epidemic.

China’s COVID-19 vaccine arrived in Luanda on March 25th. Angolan Health Minister Lutukuta said that China was the first country to provide vaccine assistance to Angola, and Angola was deeply grateful to China for its selfless help.

A batch of COVID-19 vaccines aided by China arrived at Tunis Carthage International Airport on March 25th. Minister of Health Mehdi said that Tunisia is facing the test of the third round of epidemic, and this batch of vaccine assistance from China is very timely. He emphasized that China’s emergency provision of vaccine assistance at the request of the Turkish side reflects the high level of bilateral relations. Turkey hopes to further strengthen cooperation with China in the field of health and constantly give new meaning to bilateral relations.

The second batch of Cushing COVID-19 vaccine from China arrived in Manila on the morning of March 24th. Philippine Health Minister Francisco Du Kai said that the Philippine side thanked China for its help. The epidemic situation in the Philippines has been tightening recently, and this batch of vaccines came at the right time.

The first batch of COVID-19 vaccine and some epidemic prevention materials aided by China Government arrived in Male late at night on March 24th. Naseem, Minister of Health of Malaysia, thanked the government of China and the people of China for providing vaccine assistance to Malaysia, hoping to strengthen cooperation with China and win the fight against the epidemic as soon as possible. (Reporter Yang Xun)

　　Since the outbreak of the epidemic, some rumors about the epidemic and information without scientific basis have also begun to spread like viruses, and information about health protection is the key area of rumors and rumors. Rumors stop at wise men. To identify the truth of this kind of information, we must believe in science, learn more popular science and learn more.

　　Recently, several pieces of information about COVID-19’s prevention, anti-bacteria and anti-virus have been widely circulated on the Internet. These pieces of information are ambiguous and specious, but they have attracted much attention. So, are these rumors true and have scientific basis?

　　Fear of "chlorine" on disinfectant is alarmist.

　　Recently, it was reported on the Internet that chlorine-containing disinfectants were the most sold in the market during the epidemic, and those with the word "chlorine" in their names were chlorine-containing disinfectants.

　　First of all, it is a fact that the highly effective disinfectant represented by 84 disinfectant is one of the most widely used in disinfection products in this epidemic. However, in the process of epidemic prevention and control, alcohol, peracetic acid and high-purity plant-based bacteriostatic agents are also widely used, and the use in disinfection products is adapted to local conditions.

　　Secondly, too much emphasis on "chlorine" in disinfectants will greatly reduce the effect of information dissemination and even have negative effects. Zhang Zhigang, a senior engineer specially appointed by Inner Mongolia Institute of Biotechnology, told the reporter: "Humans have been disinfecting and sterilizing with toxic chlorine for a long time, which is the toxicity of chlorine, but as long as such products are used correctly, they will basically not cause harm to the human body. For any chemical disinfection products, we must first learn the correct method and master the scientific proportion when using it. Under this premise, there is no need to worry that the chemical components in it will cause harm to the human body. "

　　Misleading people to struggle with words is the main feature of this message. In fact, disinfection products, whose names do not contain the word "chlorine", such as bleaching powder and high-efficiency anti-virus effervescent tablets, are all chlorine-containing disinfectants. As long as they are used correctly, they are basically harmless to the human body without food, drink or contact.

　　"Drinking single fir tea can prevent COVID-19" is a rumor.

　　"Drinking more single fir tea in Zhong Nanshan has a great effect on the prevention and treatment of pneumonia" and "Eating more certain food has a great effect on the prevention and treatment of pneumonia" … …

　　For such rumors that the level of rumors is seriously low, common sense can be broken. First of all, highly respected and rigorous scientists will never make such remarks publicly. Secondly, there is no such institution as the National Health Bureau in China, and the rumors are self-defeating.

　　From a scientific point of view, the single fir tea, like other teas, has a certain health preserving function, but it has nothing to do with preventing and killing Covid-19. Zhang Zhigang said: "Because single fir tea contains tea polyphenols, and tea polyphenols have biological activities such as antioxidation, bacteriostasis and enzyme inhibition, the efficacy of this tea is easy to be infinitely amplified in an extraordinary period."

　　Experts suggest that drinking tea for health preservation is scientific, but no research shows that drinking tea can prevent diseases like COVID-19, and Shan fir tea is no exception. Drinking tea can prevent the growth and spread of pneumonia virus, which is even more nonsense.

　　Abuse of eye drops "antivirus" is counterproductive.

　　"Have you heard? Levofloxacin eye drops can prevent COVID-19 virus and effectively prevent Covid-19 from infecting human body through eyes … …”

　　Recently, many people went to pharmacies to buy levofloxacin eye drops, claiming that this kind of eye drops can prevent Covid-19 from entering the eyes, which triggered a small wave of "eye-catching drugs". In this regard, our reporter connected with Fan Haining, vice president of the Affiliated Hospital of Qinghai University, who is fighting the epidemic in Wuhan. Fan Haining said that "levofloxacin eye drops prevent and treat Covid-19" is indeed a rumor. People should not blindly use antibiotics to prevent or treat Covid-19. He introduced that levofloxacin is a common eye drop, and its main active ingredient is levofloxacin hydrochloride. Levofloxacin hydrochloride, as a broad-spectrum antibacterial agent, is widely used in the treatment of urogenital system, skin and soft tissue, digestive system, septicemia, arthritis and other fields, including the treatment of mild to moderate common pneumonia, but it has no effect on COVID-19 virus. Because there is no "specific medicine" for COVID-19 virus so far, and levofloxacin is not included in the "novel coronavirus Diagnosis and Treatment Plan (Trial Seventh Edition)", antibiotics should not be used blindly.

　　"Levofloxacin is an antibiotic, not an antiviral. COVID-19 is mainly transmitted through respiratory tract, and the amount of virus exposed by breathing is more than that of eyes. Although the virus may enter the eyes by rubbing eyes and other actions, it is unlikely to be removed by eye drops. It is not recommended or advocated that people drop any eye drops by themselves for the so-called ‘ Antivirus ’ Because of the long-term abuse of levofloxacin, it will also have side effects and dependence on the cornea, and cause symptoms such as itchy eyes and sensitive irritation. The abuse of levofloxacin by allergic constitution may cause symptoms such as shock, allergy and rash. Injection of levofloxacin hydrochloride will cause a burden on the kidneys and liver. " Fan Haining said.

　　Realgar can not only prevent COVID-19, but also poison itself.

　　Recently, it was reported on the Internet that realgar can prevent COVID-19. As a matter of fact, this chemical can not only kill Covid-19, but also be poisoned if taken in excess.

　　Zhang Zhigang introduced: "Modern medicine does have clinical application to realgar. According to the information we have, realgar has played a certain anti-cancer role in mice. Clinically, it is only used in a limited range such as herpes zoster, chronic bronchitis and pterygium, and it has great damage to human renal function and digestive function, and it also has corrosive effect on human cells, but it has no connection with the treatment of COVID-19."

　　Zhang Zhigang suggested that the scientific name of realgar is arsenic tetrasulfide. If you take it for a long time, arsenic poisoning will occur. However, realgar will undergo an oxidation reaction at a certain temperature, generating highly toxic arsenic trioxide (arsenic). Therefore, in an extraordinary period, after receiving such information, we must scientifically examine and identify it, and we must not follow suit, let alone believe it.

　　Infrared thermometer is harmful to health? Rumors!

　　Recently, a news spread widely on the Internet, claiming that it is best to test the wrist when using an infrared thermometer to detect body temperature. If the infrared thermometer frequently irradiates the eyes, it will damage the retina, which will cause eye diseases such as glass lens opacity and cataract, and serious macular degeneration will occur. If the neck is measured, because it is close to the thyroid gland, improper use will also have adverse effects.

　　So, is the infrared thermometer really harmful to health? "There is no doubt that this is another rumor." Fan Haining said.

　　He introduced that in daily life, infrared devices that humans are exposed to are very common, such as ‘ Small sun ’ Heaters, massagers, electric stoves, and electrical equipment such as induction faucets, hand dryers, wireless mice, and Bluetooth headsets, which are popular in recent years. The working principle of infrared thermometer is to focus the infrared radiation of human body on the detector, and the detector will convert the radiation power into an electrical signal, which will be displayed in the unit of temperature after being compensated for the ambient temperature. The infrared thermometer does not emit infrared rays to the human body, but receives infrared radiation from the human body, and will not cause any harm to the human body.

　　At the same time, Qi Haiyan, deputy chief physician of the Department of Ophthalmology, Shunyi Women and Children Hospital of Beijing Children’s Hospital, also said in an interview with the media that the high intensity of infrared rays can cause certain irritation and damage to the eyes, which can seriously cause cataracts, retinal damage and even blindness. The eye can absorb infrared rays with a wavelength less than 1.5 microns. If the eye is directly irradiated, the liquid in the eye can react by absorbing short-wave infrared rays, causing eye diseases. "However, the infrared thermometer on the market does not emit infrared rays, but emits red light for the convenience of positioning. Its working principle is to measure by receiving the infrared wavelength in the heat emitted by the human body." Yan Haiyan said.